-
[Welfare for Oncologists] Paper book "Guide to Clinical Tumor Diagnosis and Treatment" 0 yuan free shipping
Time of Update: 2021-05-20
Appendix at the end of the book: standard medical records, a list of chemotherapy drugs, efficacy evaluation standards, and chemotherapy toxicity classification standards.
-
JCO: Lukaparib can effectively treat advanced pancreatic cancer with BRCA1/2 or PALB2 pathogenic mutations
Time of Update: 2021-05-20
In summary, Rucapriel maintenance therapy for platinum-sensitive advanced pancreatic cancer patients carrying pathogenic mutations of BRCA1, BRCA2 or PALB2 has a good curative effect and good safety .
Rucapari maintenance therapy is effective for platinum-sensitive advanced pancreatic cancer patients carrying pathogenic mutations of BRCA1, BRCA2 or PALB2 genes.
-
J Thorac Oncol: The efficacy of nano-paclitaxel vs docetaxel in the treatment of patients with advanced NSCLC
Time of Update: 2021-05-20
In summary, for patients with advanced NSCLC who have previously been treated, nab-paclitaxel is not inferior to docetaxel in terms of overall survival .
For patients with previously treated advanced NSCLC, nab-paclitaxel is not inferior to docetaxel in terms of overall survival.
-
Sci Transl Med: Can the metastatic sentinel lymph node be detected by taking a photo during cancer surgery?
Time of Update: 2021-05-20
In the operating room, during the surgical resection of 18 breast cancer patients, the image sensor used clinically approved near-infrared fluorophores to further locate the sentinel lymph nodeIn summary, the flexibility and performance provided by this simple and compact architecture highlights the advantages of bio-inspired sensors in image-guided surgery .
-
Eur J Cancer: Efficacy and safety of gemcitabine + albumin-bound paclitaxel versus FOLFIRINOX as first-line treatment of advanced pancreatic cancer
Time of Update: 2021-05-20
Pancreatic cancerThis study aims to compare the efficacy and safety of gemcitabine + albumin-bound paclitaxel (GN) versus FOLFIRINOX as the first-line treatment of advanced pancreatic cancer.
This study aims to compare the efficacy and safety of gemcitabine + albumin-bound paclitaxel (GN) versus FOLFIRINOX as the first-line treatment of advanced pancreatic cancer.
-
JNCCN: The relationship between bone metastasis, bone-related events and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors
Time of Update: 2021-05-20
Bone metastasis at baseline is a poor prognostic factor for ICIs in the treatment of metastatic NSCLC, and the application of BMAs cannot prevent the occurrence of SREs and improve the prognosis of patients.
-
J Clin Invest: The clinical activity of BCMA-specific CAR T cells in the treatment of multiple myeloma
Time of Update: 2021-05-20
gov/30896447/" target="_blank" rel="noopener">B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma .
gov/30896447/" target="_blank" rel="noopener">B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma in this message
-
Bone Marrow Transplant: Donor-derived anti-CD19 CAR-T cell therapy can safely and effectively treat B-ALL recurrence after allogeneic hematopoietic stem cell transplantation
Time of Update: 2021-05-20
In summary, this study shows that donor-derived anti-CD19 CAR T cell therapy is a safe and effective therapy for B-ALL recurrence after allogeneic hematopoietic stem cell transplantation, and may be superior to DLI.
-
J Clin Oncol: Efficacy and safety of levatinib in the treatment of anaplastic thyroid cancer
Time of Update: 2021-05-20
03093">Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer .
03093">Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer in this message
-
Clin Lymphoma Myeloma Leuk: CAR-T therapy can be used to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
Time of Update: 2021-05-20
In summary, the results of this prospective study show that allogeneic donor-derived anti-CD19 CAR T cell therapy is a safe and effective rescue plan, suitable for relapsed/refractory B-cell acute lymphocytes after allogeneic hematopoietic stem cell transplantation Patients with leukemia.
-
Cancer: The effect of HIV-1 protease inhibitor nelfinavir combined with standard radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer
Time of Update: 2021-05-20
Nelfinavir (NFV) is an HIV-1 protease inhibitor that has been shown to increase the sensitivity of cancer cells to chemical radiation (CRT)This study is a phase 1 clinical trial to evaluate the safety of NFV for locally advanced cervical cancer and determine the recommended phase 2 clinical trial dose of NFV combined with simultaneous CRT for the treatment of locally advanced cervical cancer.
-
What should the child do if the mother undergoes chemotherapy?
Time of Update: 2021-05-20
The triple regimen containing NK-1 receptor antagonists is preferred to help these patients reduce nausea and vomiting caused by chemotherapy and improve Quality of Life.
-
Nat Med: Durvalumab combined with targeted therapy for advanced urothelial cancer
Time of Update: 2021-05-20
This study (NCT02546661, BISCAY) combined durvalumab with related targeted therapies in biomarker-selected chemotherapy-refractory AUC populations, mainly in combination with the above three drugs: (1) Pairs with FGFR DNA mutations ( FGFRm) tumors combined with FGFR (fibroblast growth factor receptor) inhibitors; (2) combined with PARP (poly-ADP ribose polymerase) pharmacological inhibitors for tumors with and without DNA homologous recombination repair defects (HRRm); (3) Combined use of TORC1/2 inhibitors for tumors with DNA mutations in the mTOR/PI3K pathway.
-
Lancet Oncology: Atezolizumab's global phase 3 clinical trial showed poor efficacy for advanced bladder cancer
Time of Update: 2021-05-20
406 patients in the experimental group received an intravenous injection of 1200 mg of atezolizumab every 3 weeks, and 403 patients in the control group remained under observation after surgery without additional treatment.
-
J Clin Oncol: Apalutamide combined with ADT can effectively improve the prognosis of metastatic castration-sensitive prostate cancer
Time of Update: 2021-05-20
In summary, the final results of the TITAN trial proved that even if there is a crossover between the intervention groups, apalutamide combined with ADT treatment can improve the OS of mCSPC patients, delay the onset of castration resistance, maintain health-related quality of life , and be safe Sex can be.
-
Leuk Lymphoma: CD19 CAR T therapy can be used to treat patients with recurrent Ph+ALL with T315I mutation
Time of Update: 2021-05-20
In summary, the results of this study confirmed the efficacy of anti-CD19 CAR T cell therapy in the treatment of recurrent Ph+ALL with T315I mutation before and after allo-HSCT, and the therapy can be used in combination with Pranatinib.
-
Lancet Haematol: Combined infusion of humanized anti-CD19 and anti-BCMA CAR T cells or a new therapy for the treatment of relapsed or refractory multiple myeloma
Time of Update: 2021-05-20
Researchers from the Affiliated Hospital of Xuzhou Medical University in China conducted a single-center, single-arm, phase 2 clinical trial to evaluate the combination of humanized anti-CD19 and anti-BCMA CAR T cells in relapsed or refractory multiple myeloma The results of the study on activity and safety in patients have been published in Lancet Haematol.
-
JCO: Efficacy and safety of Pembrolizumab combined with Ipilimumab in the treatment of melanoma with PD1/PDL1 inhibitor failure
Time of Update: 2021-05-20
Progression-free time and duration of clinical response 87% (62/70) of the patients had any degree of treatment-related adverse events , the common ones were skin itching, rash, diarrhea, fatigue, nausea, and elevated transaminases .
-
Takeda China
Time of Update: 2021-05-10
On the 26th, Takeda China announced to employees that Huang Haoyu formally joined Takeda China as the head of the anti-tumor division and became a member of Takeda China’s leadership team.
He has worked in Bayer Schering, Sanofi, Novartis, Roche, AbbVie has held important positions in the anti-tumor product business of five multinational pharmaceutical companies.
-
Howson "joined" CSPC successfully "sniped" Pfizer's sunitinib patent and was invalidated!
Time of Update: 2021-05-10
In February 2021, the State Intellectual Property Office issued the "Administrative Adjudication Measures for the Early Resolution Mechanism for Pharmaceutical Patent Disputes (Draft for Comment)" which did not mention the encouragement of the first successful patent challenge and the first approved chemical generic drug applicant Matters.
